Is ranolazine an antiarrhythmic drug?

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 294, Issue 5, 2008, Pages

  Eckhardt, Lee L ^a   Teelin, Tom C ^a   January, Craig T ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RANOLAZINE; ACETANILIDE DERIVATIVE; ANTIARRHYTHMIC AGENT; CALCIUM; CARDIOTONIC AGENT; CHELATING AGENT; PIPERAZINE DERIVATIVE; SODIUM; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT;

ANTIARRHYTHMIC ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; EDITORIAL; HEART ARRHYTHMIA; HUMAN; NONHUMAN; PRIORITY JOURNAL; ACTION POTENTIAL; ANIMAL; HEART ATRIUM; HEART MUSCLE CELL; HEART MUSCLE CONDUCTION SYSTEM; METABOLISM; NOTE; PATHOPHYSIOLOGY; SUPRAVENTRICULAR TACHYCARDIA; TIME; UPREGULATION;

ACETANILIDES; ACTION POTENTIALS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; CALCIUM; CARDIOTONIC AGENTS; CHELATING AGENTS; HEART ATRIA; HEART CONDUCTION SYSTEM; HUMANS; MYOCYTES, CARDIAC; PIPERAZINES; SODIUM; SODIUM CHANNEL BLOCKERS; SODIUM CHANNELS; TACHYCARDIA, SUPRAVENTRICULAR; TIME FACTORS; UP-REGULATION;

EID: 44949100421     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00285.2008     Document Type: Editorial

References (30)

1. Antzelevitch C, Belardinelli L, Zygmunt AC, Burashnikov A, Di Diego JM, Fish JM, Cordeiro JM, Thomas G. Electrophysiologic effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 110: 904-910, 2004.
2. Belardinelli L, Shryock JC, Fraser H. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart 96: 6-14, 2006.
3. Boutjdir M, El-Sherif N. Pharmacological evaluation of early afterdepolarisations induced by sea anemone toxin (ATXII) in dog heart. Cardiovasc Res 25: 815-819, 1991.
4. Burashnikov A, Di Diego JM, Zygmunt AC, Belardinelli L, Antzelevitch C. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation. Circulation 116: 1449-1457, 2007.
5. Chaitman BR, Pepine CJ, Parker JO, Skopal J, Chumakova G, Kuch J, Wang W, Skettino SL, Wolff AA. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 291: 309-316, 2004.
6. Chaitman BR, Skettino SL, Parker JO, Hanley P, Meluzin J, Kuch J, Pepine CJ, Wang W, Nelson JJ, Herbert DA, Wolff AA. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 43: 1375-1382, 2004.
7. 2+ triggers early afterdepolarizations and Torsades de Pointes in rabbit hearts with type 2 long QT syndrome. J Physiol 543: 615-631, 2002.
8. Fredj S, Sampson KJ, Liu H, Kass RS. Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action. Br J Pharmacol 148: 16-24, 2006.
9. 2+-activated non-selective cation channel in human atrial cardiomyocytes. J Physiol 558: 75-83, 2004.
10. Isenberg G, Raven U. The effects of the Anemonia sulcata toxin (ATX-II) on membrane currents of isolated mammalian myocytes. J Physiol 357: 127-149, 1984.
11. 2+ current. Circ Res 64: 977-990, 1989.
12. Ju YK, Saint DA, Gage PW. Hypoxia increases persistent sodium current in rat ventricular myocytes. J Physiol 497: 337-347, 1996.
13. Marban E, Robinson SW, Wier WG. Mechanisms of arrhythmogenic delayed and early afterdepolarizations in ferret ventricular muscle. J Clin Invest 78: 1185-1192, 1986.
14. Morrow D, Scirica BM, Karwatowska-Prokopezuk E, Murphy SA, Budaj A, Varshavsky S, Wolff AA, Skene A, McCabe CH, Braunwald E. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes; the MERLIN-TIMI 36 randomized trial. JAMA 297: 1775-1783, 2007.
15. Nordin C. Computer model of electrophysiological instability in very small heterogeneous ventricular syncytia. Am J Physiol Heart Circ Physiol 272: H1838-H1856, 1997.
16. Nordin C, Ming Z. Computer model of current-induced early afterdepolarizations in guinea pig ventricular myocytes. Am J Physiol Heart Circ Physiol 268: H2440-H2459, 1995.
17. 2+. Heart Rhythm 3: 67-69, 2006.
18. Schram G, Zhang L, Derakhchan K, Ehrlich JR, Belardinelli L, Nattel S. Ranolazine: ion-channel-blocking actions and in vivo electrophysiological effects. Br J Pharmacol 142: 1300-1308, 2004.
19. Schreibmayer W, Kazerani H, Tritthart HA. A mechanistic interpretation of the action of toxin II from Anemonia sulcata on the cardiac sodium channel. Biochim Biophys Acta 901: 273-282, 1987.
20. Scirica BM, Morrow DA, Hod H, Murphy SA, Belardinelli L, Hedgepeth CM, Molhoek P, Verheugt FW, Gersh BJ, McCabe CH, Braunwald E. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 116: 1647-1652, 2007.
21. Song Y, Shryock JC, Belardinelli L. An increase of late sodium current induces delayed afterdepolarizations and sustained triggered activity in atrial myocytes. Am J Physiol Heart Circ Physiol (February 29, 2008); doi: 10.1152/ajpheart.00285.2008.
22. Na in guinea pig ventricular myocytes. J Cardiovasc Pharmacol 44: 192-199, 2004.
23. Stone PH, Gratsiansky NA, Blokhim A, Huang IZ, Meng L. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol 48: 566-575, 2006.
24. Studenik CR, Zhou Z, January CT. Differences in action potential and early afterdepolarization properties in LQT2 and LQT3 models of long QT syndrome. Br J Pharmacol 132: 85-92, 2001.
25. Ter Keurs HE, Boyden PA. Calcium and arrhythmogenesis. Physiol Rev 87: 457-506, 2007.
26. Undrovinas AI, Maltsev VA, Sabbah HN. Repolarization abnormalities in cardiomyocytes of dogs with chronic heart failure: role of sustained inward current. Cell Mol Life Sci 55: 494-505, 1999.
27. Undrovinas AI. Ranolazine improves abnormal repolarization, and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current. J Cardiovasc Electrophysiol 17: 161-177, 2006.
28. Valdivia CR, Chu WW, Pu JL, Foell JD, Haworth RA, Wolff MR, Kamp TJ, Makielski JC. Increased late sodium current in myocytes from a canine heart failure model and from failing human hearts. J Mol Cell Cardiol 38: 475-483, 2005.
29. Wu L, Shryock JC, Song Y, Li Y, Antzelevitch C, Belardinelli L. Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome. J Pharmacol Exp Ther 310: 599-605, 2004.
30. Zeng J, Rudy Y. Early afterdepolarizations in cardiac myocytes: mechanism and rate dependence. Biophys J 68: 949-964, 1995.